Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection
Additive Effect of Endonase on the Efficacy of Bismuth-containing Quadruple Therapy as Second-line Treatment for Helicobacter Pylori Infection
Sponsor: Chuncheon Sacred Heart Hospital
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Chuncheon Sacred Heart Hospital
Other Helicobacter Pylori Infection trials with similar outcome
A NA clinical study on Helicobacter Pylori Infection, this trial is terminated or withdrawn. The trial is conducted by Chuncheon Sacred Heart Hospital and has accumulated 6 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated NA
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chuncheon Sacred Heart Hospital
For direct contact, visit the study record on ClinicalTrials.gov .